STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

Ligandrol recomp stacks (SARM multi-agent culture)

Also known as

SARM stacks · RAD+LGD culture threads · LGD recomp stacks · Ligandrol stack · LGD-4033 stacks · LGD + RAD stack · LGD + ostarine stack · LGD + Cardarine stack · LGD + MK-677 stack · SARM stack culture (multi-agent discussion unit) · multi-SARM recomp cycle · kitchen-sink SARM blend

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Niche talk Systemic Oral SARMs (adjacent discourse)

Systemic oral multi-agent stacks — whole-body androgen-receptor (and often non-SARM adjunct) exposure.

What people say This is a discussion unit for oral multi-agent stacks centered on LGD-4033, not one compound. Each SARM or adjunct keeps its own amount, evidence, effects and risks. Doses people talk about
LGD plus ostarine reportLGD-4033 10 mg + ostarine 10 mg each morning

One Reddit user reported using both for almost a month and noticing less soreness; product identity and outcomes were unverified.

Same-author dose changeLGD-4033 10→15 mg/day + ostarine 15→22.5 mg/day

Same thread: weeks 1–4 used the lower component amounts and the last six weeks the higher amounts; reported gain was described as mostly water and early malaise occurred.

Published co-administration caseLGD-4033 10 mg/day + MK-677 15 mg/day oral

One 25-year-old man used both for five weeks; body mass, lean mass and fat mass rose while several endocrine, lipid and liver measures worsened.

These are uncontrolled gray-market accounts, not endorsed regimens. A planned stack is not an outcome, and label amounts may not match contents.

Half-life & effect duration

Half-life in the body
  • LGD-4033 componentAbout 24–36 hours
  • RAD-140 component · clinical estimatesAbout 45–60 hours
  • Ostarine component · secondary estimateAbout 24 hours
  • MK-677 · parent-plasma secondary estimateAbout 4–6 hours
  • Cardarine · community estimateAbout 12–24 hours
Felt duration people report
  • Reported course patternsFeeling bad for the first 3 days, less soreness after weeks, or lethargy around week 5
  • Other accountsLittle added benefit from stacking
Timing context & sources
How it may feel Reports range from little early sensation to reduced soreness, water-weight gain or strength changes; lethargy and libido or mood problems are often discussed later. None identifies a stack-specific response curve.
Cycles people discuss Community plans commonly span six to eight weeks, sometimes longer, while the controlled LGD studies used lower single-agent amounts. Stack calendars are not clinical protocols. Timing LGD-centered stack templates usually place oral components once daily across 6–8-week runs. Post-cycle discussions disagree between starting the day after the last dose and waiting days to about 1–2 weeks; neither is a validated stack clock. Stacks Inspected reports cover LGD with ostarine, MK-677, S-4 or other agents. Results and adverse effects cannot be assigned cleanly when components, training, diet and post-cycle drugs change together. Watch for Product / mislabel risk (structural): JAMA 2017 — of 44 products sold as SARMs, only ~52% contained a SARM; ~39% another unapproved drug; ~25% substances not on the label; ~9% no active; only ~41% matched labeled amount. Stacks and blends magnify this.
Related
LGD-4033RAD-140OstarineYK-11

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

LGD-4033 alone showed a 24–36-hour half-life and roughly threefold accumulation by day 21 in the reviewed healthy-men study.

This describes the LGD component only. Ostarine, RAD-140, MK-677 and Cardarine have separate kinetics, so a named stack has no single parent-drug half-life.

The trial used 0.1–1.0 mg/day for 21 days, far below many community LGD amounts and without the co-agents in the reports.

Felt duration people report

Reports include feeling bad for the first three days, reduced soreness by several weeks, and lethargy around week five, but other users reported little added benefit from stacking.

Different authors used different agents and component amounts; some posts were plans rather than completed outcomes.

Uncontrolled reports with unverified products, training and diet confounds, selective follow-up and no common outcome measure.

  • r/sarmssourcetalk — LGD + Ostarine stack (opens in a new tab)Visible replies include 10 mg of each every morning for almost a month; a separate same-author course used LGD 10 then 15 mg/day with ostarine 15 then 22.5 mg/day and reported mostly water-weight gain, early malaise and later leanness with some fat gain. Another commenter described lethargy around week five.Multiple uncontrolled authors, unverified products and self-selected outcomes; later training, diet and post-cycle treatment confound attribution.
  • r/sarmssourcetalk — Is stacking LGD-4033 with Ostarine useless? (opens in a new tab)Visible discussion contains conflicting claims about added benefit versus extra suppression and water; one commenter reports 2.5–5 mg LGD with 15 mg S-4 and 10 mg MK-677 for sleep in winter.Thread mixes personal use, theory and recommendations; products and outcomes are unverified and the reported regimen is not an LGD-plus-ostarine outcome.
  • r/sarmssourcetalk — Last cycle stacking LGD, Ostarine and Cardarine (opens in a new tab)Original post proposes LGD 20 mg/day for eight weeks, ostarine 25 mg/day for seven weeks and Cardarine 10 mg/day for seven weeks; replies advise removing ostarine or lowering LGD.A proposed regimen and comment debate, not a completed exposure or outcome report.

Other context in this card

What people say 12

  • Recomp claim (community core): Simultaneous fat loss + muscle retention (or small lean gain) under deficit/near-maintenance + lifting — diet almost always co-credited. forum
  • Strength (community): Faster progression on compounds when LGD is paired with RAD or ostarine is a frequent log theme; confounded by calories, sleep, and novelty. forum
  • Look typology (aesthetic only): LGD credited for fuller/rounder “wetter” mass; RAD or ostarine for drier/harder lines; Cardarine for conditioning/endurance photos — typology and lighting, not imaging RCTs of stacks. forum
  • Cut hold: LGD ± ostarine or LGD + Cardarine frequently credited for size under hard deficits. forum
  • Cardarine add-on narrative: Longer steady-state cardio, easier deficit adherence, “fat oxidation” talk from PPARδ agonist culture — separate mechanism from AR SARMs. forum
  • MK-677 add-on narrative: Better sleep, hunger, recovery feel; can blunt fat-loss goals if surplus or binge eating grows. forum
  • Vendor / forum stack menus (recreational literature summaries): Examples summarized in pharmacy reviews of fitness-site advice — e.g. andarine + LGD for short “strength” blocks; andarine + ostarine + Cardarine for “recomp”; RAD + LGD for max mass — all anecdotal chart culture, not trials. forum
  • What stacks do not prove: Multi-agent logs cannot isolate which molecule drove scale, DEXA, or strength; kitchen-sink blends make attribution worse. forum
  • LBM (single-agent LGD trial, not a stack): Basaria 2013 — 0.1 / 0.3 / 1.0 mg LGD daily × 21 days in healthy men; lean mass rose dose-dependently; ~1.2 kg LBM often cited at 1 mg/3 weeks; fat mass did not change significantly in that short window. trial
  • LBM (VK5211 Phase 2, clinical recovery — not gym stack): ~0.5 / 1 / 2 mg daily × 12 weeks in hip-fracture recovery — placebo-adjusted LBM roughly +4.8% / +7.2% / +9.1%; not a recreational multi-agent study. trial
  • Cardaci 2022 stack signal (n=1): 25-year-old male, LGD-4033 10 mg + MK-677 15 mg daily × 5 weeks — body mass +6.0%, total LBM +3.1%, appendicular LBM +4.3%, but total fat mass +15.4% and large adverse biomarker shifts (see sides). Single case, not a recomp protocol proof. trial
  • Missing evidence: No head-to-head RCT of LGD-only vs LGD+RAD vs LGD+ostarine vs LGD+GW at recreational mg for recomp outcomes. trial

Doses people talk about 18

  • LGD as stack core (community): Multi-agent logs describe ~2.5–5 mg/day, ~5–10 mg/day, and sometimes 10–15+ mg/day of LGD itself. These are component amounts, not total stack mass or safety tiers. forum
  • LGD recreational reviews (summarized): Fitness-blog guidance often cites 5–10 mg daily for 6–10 weeks, with extra testosterone-suppression concern language above ~10 mg — still far above multi-dose trial daily doses. forum
  • RAD-140 with LGD (community dual-SARM): RAD commonly ~5–10 mg/day first dual runs; ~10–20 mg/day intermediate; ~20–30 mg/day advanced/aggressive talk — forums repeatedly warn dual strong SARMs compound suppression without proven better risk/benefit. forum
  • Ostarine with LGD (community): Ostarine often ~10–25 mg/day (some charts to ~30 mg) as the “milder hold / recomp bridge” arm next to LGD. forum
  • Cardarine with LGD (community; not a SARM): ~10–20 mg/day oral for endurance/cut/recomp stacks; anti-doping literature also notes ~10–20 mg/day for ~6–8 weeks as a reported abuse pattern. forumtrial
  • MK-677 with LGD (community): ~10–25 mg/day (Cardaci case used 15 mg with 10 mg LGD). Hunger can fight cut goals. forumtrial
  • Example dual-SARM template language (forums/vendor blogs): LGD 5–10 mg + RAD 10–20 mg once daily for ~6–8 weeks is a repeatedly posted “hard recomp / lean bulk” pattern — not a study arm. forum
  • Example cut/recomp template language: LGD 5–10 mg + Cardarine 10–20 mg (± ostarine 10–20 mg) under deficit; some add MK-677 and then complain hunger killed the cut. forum
  • Capsule fixed-mg products: Easier counting but still unverified without third-party testing; multi-SARM “one pill stack” products hide per-agent control. forum
  • Uncertainty: Gray-market label mg ≠ verified actives; multi-agent blends amplify mislabel/adulteration risk. forum
  • Andarine (S-4) pairings in recreational chart culture (summarized in pharmacy reviews of fitness sites): e.g. S-4 ~50 mg + LGD ~10 mg short “strength” blocks; S-4 ~50 mg + ostarine ~25 mg + Cardarine ~20 mg for “recomp” length charts (~9–12 weeks in those menus); S-4 ~25 mg + Cardarine ~20 mg for cut — all third-party blog culture, zero RCTs. forum
  • Kitchen-sink / pre-blend capsules: Products have been labeled with multi-agent combos (e.g. literature/case contexts describing capsules listing MK-2866, GW-501516, MK-677, LGD-4033, and RAD-140 on one label) — ratios and true contents vary; dose control and attribution are poor. trialforum
  • Liquid math risk: Stacking 2–4 research liquids multiplies under/over-measurement; users often discuss written daily logs and labeled droppers to avoid double-dosing. forum
  • LGD single-dose clinical exposure note: Ascending single oral doses up to ~22 mg reported in first-in-human Phase 1 abstract data — not a multi-week stack arm. trial
  • Dose vs trial honesty: Community LGD 5–10 mg × 6–10 weeks (± second SARM) is not the same exposure as Basaria ≤1 mg × 21 days or VK5211 ≤2 mg × 12 weeks. trial
  • Framing: Figures in this section are community, vendor-chart, recreational-review, or named-trial numbers for research literacy only — not prescriptions, not safety-validated athletic protocols, not medical advice. Stack ratios and labels vary by seller. forum
  • LGD trial multi-dose (healthy men): 0.1, 0.3, or 1.0 mg oral once daily × 21 days (Basaria 2013). trial
  • LGD trial multi-dose (VK5211 hip-fracture Phase 2): 0.5, 1.0, or 2.0 mg oral once daily × 12 weeks. trial

How it may feel 8

  • Days 1–7: Usually little stimulant “buzz.” Early notes: pumps/fullness (LGD lore), denser training feel (RAD lore), or easier cardio if Cardarine is in the mix. Headache/dry mouth can appear (also listed in early LGD clinical AE summaries). forum
  • Weeks 1–2: Strength or session quality often rises before mirror changes; libido/mood may start shifting as suppression builds — highly individual. MK-677 hunger/sleep changes can show early. forum
  • Weeks 2–3: Aligns with the only multi-dose healthy-men LBM window for solo LGD (21 days ≤1 mg); stack users at 5–10× those doses often already talking scale weight and water. trialforum
  • Weeks 3–4: Common recomp photo/check-in and first mid-cycle bloodwork talk (T, lipids, AST/ALT). Dual-SARM stacks get earlier “am I suppressed?” chatter than mild solo ostarine lore. forum
  • Weeks 6–8: Typical peak of 6–8 week stack templates; suppression, HDL anxiety, fatigue, and “stack fatigue” (harder to know what to drop) cluster here. forum
  • Weeks 8–12: Longer aggressive multi-agent runs — lipid/liver/PCT talk dominates more than novelty gains; diminishing returns debated. forum
  • On-cycle crash while still dosing: Some dual-SARM logs describe mid-cycle lethargy or flat libido when suppression outruns perceived anabolism. anecdote
  • End of cycle / first off weeks: Energy, libido, and soft training dips; multi-agent crashes often described as harsher than single-agent low-mg runs. forum

Cycles people discuss 13

  • Typical multi-agent length: 6–8 weeks on is the modal LGD-centered recomp/bulk stack window. forum
  • Extended charts: 8–10 or 8–12 weeks in intermediate/aggressive multi-SARM or LGD+RAD write-ups; longer = more lipid/suppression/liver talk. forum
  • Shorter intros: ~4–6 week first dual runs or “product authenticity” tests appear in cautious logs. forum
  • Solo-first culture vs stack-first: Careful communities often advise a solo LGD or solo ostarine first cycle before dual SARMs so sides and bloodwork are attributable; stack-first is still common in vendor marketing. forum
  • PCT talk (near-default after multi-SARM): SERM-style post-cycle language — tamoxifen (Nolvadex) and/or clomiphene (Clomid) for roughly ~3–6 weeks after the run is widely discussed; this is research-chem culture, not an FDA-labeled LGD regimen. forum
  • When PCT starts (debate): Some start the day after last dose; others wait days to ~1–2 weeks citing long SARM half-lives (especially RAD clinical ~45 h class) — both patterns circulate. forum
  • On-cycle SERM “bridge” minority talk: Low-dose tamoxifen through an LGD+RAD cycle appears in some dual-SARM threads — contested, not evidence-based standard. forum
  • Time off rule of thumb: Off-cycle length ≥ on-cycle (plus PCT/recovery) is a frequent heuristic; evidence is anecdotal. forum
  • Bloodwork checkpoints discussed: Pre, mid (~week 3–5), end-of-cycle, and post-PCT — total/free T, LH/FSH, SHBG, estradiol, full lipid panel, AST/ALT, sometimes CBC/glucose (especially if MK-677 is included). forum
  • Seasonal patterning: Bulk (LGD+RAD or LGD+MK) → recomp (LGD+ostarine or LGD+GW) → cut (ostarine/GW-forward) is a common yearly narrative; multi-year stack safety is unknown. forum
  • Re-runs: After subjective recovery and/or labs; stacking more agents each season without isolation is a criticized pattern. forum
  • Example PCT shapes (forum only — not medical protocols): Nolvadex often ~10–20 mg/day for ~4 weeks; Clomid at lower multi-week charts or short dual-SERM runs; “front-load then taper” PCT language is common in nonmedical guides. forum
  • Exit flags in community lore: Crushing libido/energy, jaundice/dark urine/pruritus, sharp lipid crash, rising enzymes, or stalled recomp with heavy suppression — stop-and-reassess talk, not medical algorithms. forum

Timing 15

  • Ostarine half-life talk: Roughly ~24 hours class in secondary summaries — once daily common. forum
  • Cardarine timing culture: Often once daily or split; not AR-SARM PK. forum
  • MK-677 timing culture: Night dosing for sleep/appetite lore is common; not a SARM. forum
  • Stack schedule practice: Most logs dose all orals once daily at a consistent time; “simple timing” preferred over complex multi-split charts when 3+ bottles are open. forum
  • Hormones (stack assumption): Dual SARM (LGD+RAD) assumed deeper/harder-to-recover suppression than solo low-mg LGD — supported by community bloodwork volume, not a multi-agent RCT. forum
  • After stop (community multi-agent): Subjective recovery often multi-week with or without PCT; dual-SARM + MK-677 crashes frequently described as longer. forum
  • LGD half-life: ~24–36 hours; once-daily oral is the trial and community default. trial
  • LGD accumulation: Linear/dose-proportional PK; plasma levels roughly ~3-fold higher at day 21 vs day 1 at 0.1–1 mg/day in Phase 1. trial
  • RAD-140 half-life (clinical oncology PK): Mean t½ often cited ~45–60 hours (Phase 1 ~44.7 h reported) — longer than many old vendor “16–20 h” copies; supports QD dosing and later PCT-start arguments. trial
  • Hormones (solo LGD trial): Dose-dependent suppression of total testosterone and SHBG; free T and FSH clearer at 1.0 mg; LH/PSA not meaningfully changed in the short Phase 1; markers trended back over weeks after stop. trial
  • Cardaci co-admin endocrine snapshot: On LGD 10 mg + MK-677 15 mg × 5 weeks — free T −85.7%, total T −62.3%, SHBG −79.6%; FSH below reference on- and post-cycle in that subject. trial
  • Lipids (solo LGD Phase 1): HDL and triglycerides fell on treatment; total/LDL generally not significantly changed in that short study; recovery toward baseline after discontinuation in the clinical window. trial
  • Lipids (Cardaci stack): HDL −36.4%, LDL +40%, triglycerides +39%, total cholesterol +14.8% on-cycle — illustrates multi-agent biomarker cost in one published n=1. trial
  • After stop (clinical solo LGD): Hormones/lipids recovered over follow-up weeks after short low-dose exposure. trial
  • Anti-doping: Parent SARMs plus metabolites (and GW-501516 separately) are WADA-prohibited; multi-agent use multiplies detection targets and windows for tested athletes. trial

More on what it is 8

  • What it is: A discussion unit, not a single molecule — multi-compound oral “recomp” stacks centered on LGD-4033 (Ligandrol / VK5211) plus one or more partners from gray-market SARM/PED culture. forum
  • Why “recomp”: Users search for fat-loss and muscle-hold (or mild gain) at once under training + diet, often framed as avoiding full injectable AAS cycles. forum
  • Core agent: LGD-4033 is the mass/fullness / strength anchor in most named “Ligandrol recomp” templates. forum
  • Most-cited partners: RAD-140 (Testolone), ostarine (MK-2866 / enobosarm), Cardarine (GW-501516 — not a SARM), MK-677 (ibutamoren — GH secretagogue, not a SARM), and older andarine (S-4) pairings. forum
  • Mechanism frame (stack-level): Dual/triple AR agonism (LGD ± RAD ± ostarine) plus optional PPARδ endurance/fat-oxidation (Cardarine) and/or GH-axis appetite/sleep (MK-677). forum
  • Evidence honesty: Single-agent LGD has short human trial data (Basaria Phase 1; VK5211 hip-fracture Phase 2). Named multi-SARM recomp stacks have no quality RCTs. One published case report co-administered LGD + MK-677 (Cardaci 2022). trial
  • Product reality: Pre-blended multi-SARM capsules and “stack” bottles are common; a JAMA 2017 analysis of 44 products marketed as SARMs found only ~52% contained a SARM, ~39% another unapproved drug, ~25% unlabeled extras, ~9% no active — label mg is not identity proof. trial
  • Not this: Not a clinical protocol, not FDA-approved for any physique use, not proven “safer than steroids,” not a dietary supplement. trial

Stacks 14

  • LGD + RAD-140 (“hard recomp / lean bulk”): The signature dual strong-SARM pairing — size/fullness (LGD) + dry strength look (RAD). Highest dual-SARM suppression and side-load talk; no quality head-to-head RCT. Common chart language: LGD ~5–10 mg + RAD ~10–20 mg × ~6–8 weeks. forum
  • LGD + ostarine (MK-2866): Mass + milder muscle-hold arm; ostarine framed as gentler than RAD for recomp beginners who still want two AR agents — still multi-agent risk. forum
  • LGD + Cardarine (GW-501516): Strength/mass + endurance/cut narrative; GW is not a SARM and carries separate long-term safety discourse (including multi-organ rodent carcinogenicity at high developmental exposures). forumanimal
  • LGD + MK-677 (Ibutamoren): Extremely common “size + sleep/appetite” bulk stack; Cardaci 2022 is the main published human co-admin case (LBM and fat both up; lipids/liver/hormones worsened on-cycle). Hunger can sabotage recomp deficits. trialforum
  • LGD + RAD + Cardarine (“LGD+RAD+GW”): Aggressive recomp/cut forum templates — max attribution failure and max multi-pathway risk talk. forum
  • LGD + RAD + MK-677 (± Cardarine): Kitchen-sink bulk; forum posts sometimes treat this as the “incredible stack” while others call it untrainable for side isolation. forum
  • Andarine (S-4) + LGD (older strength charts): Recreational menus have listed short S-4 ~50 mg + LGD ~10 mg blocks; S-4 yellow-tint vision lore is a separate side channel. forum
  • Andarine + ostarine + Cardarine (recomp menus without LGD): Parallel multi-agent recomp culture that sometimes substitutes for LGD-centered templates. forum
  • LGD + YK-11: Niche hardness/myostatin-lore stack; thinner human data and harsh side reputation. forum
  • PCT as planned stack piece: Tamoxifen and/or clomiphene after the run are routinely listed on the same cycle template as the on-cycle agents. forum
  • Support-compound talk: Fish oil / lipid support, TUDCA/NAC/milk thistle “liver support,” sleep and protein non-negotiables — efficacy of OTC support specifically for multi-SARM stacks is unevenly evidenced. forum
  • Avoid-stack warnings in communities: Other hepatotoxic orals, heavy alcohol, and unsupervised megastacks called out as risk multipliers after multi-agent DILI case reports. forum
  • Pre-made blend warning: Fixed multi-SARM capsules prevent dropping the worst-tolerated agent mid-cycle and obscure true mg of each active. forum
  • Test-base debate: Advanced forums argue real testosterone (TRT/blast) as a base instead of multi-SARM-only; others stay oral-only for needle aversion — cultural split, not medical guidance. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 22

  • Suppression worse in stacks (community consensus): Dual SARMs (especially LGD+RAD) and LGD+MK multi-week runs are widely described as more suppressing than solo mild ostarine — libido loss, fatigue, mood dips, soft post-cycle gains. forum
  • HDL / lipids (stack case + community): Cardaci stack showed HDL −36.4%, LDL +40%, triglycerides +39%; forum multi-SARM panels frequently flag worsened ratios. Multi-oral stacking is assumed to worsen the lipid picture vs solo low-mg trial exposures. trialforum
  • MK-677 adjunct sides: Hunger, water retention, fasting glucose concern, and potential cut sabotage — plus co-admin biomarker cost in Cardaci. forumtrial
  • Andarine vision lore (if S-4 is stacked): Yellow tint / night-vision complaints are a classic S-4 side channel independent of LGD. forum
  • Mixed nonspecific sides: Headache, nausea, water retention, hair shed, acne, sleep disruption, irritability — hard to pin to one agent in a multi-bottle stack. forum
  • Women / virilization: Multi-SARM exposure with poorly characterized masculinization risk; many communities steer women away from dual strong SARMs. forum
  • Recovery unknowns: Dual-SARM + adjunct PCT charts ≠ systematic recovery data; clinical hormone recovery after short low-dose solo LGD does not prove multi-month multi-mg stack recovery. forum
  • Unapproved-drug status: SARMs are not FDA-approved for human use and are not legal dietary-supplement ingredients. This card maps forum talk only — not a sourcing guide, not a safety claim, and not a promise of results. trial
  • HPTA suppression (solo LGD trial baseline): Dose-dependent drop in total testosterone and SHBG at 0.1–1 mg × 21 days; free T/FSH clearer at 1 mg; recovery over follow-up weeks after short low-dose exposure. trial
  • Cardaci co-admin suppression: Free T −85.7%, total T −62.3%, SHBG −79.6% on LGD 10 mg + MK-677 15 mg × 5 weeks; FSH remained below reference post-cycle in that subject. trial
  • HDL / lipids (solo LGD Phase 1): HDL and triglycerides decreased on treatment — core trial finding and stack bloodwork focus. trial
  • Liver — controlled LGD trials: AST/ALT not significantly altered at Phase 1 doses studied. trial
  • Liver — recreational DILI (LGD and multi-SARM products): Multiple published cases of drug-induced liver injury (hepatocellular and/or cholestatic patterns) after off-label SARM products including LGD alone or LGD+RAD-class products; jaundice, pruritus, enzyme/bilirubin rises, sometimes peaking after cessation. Declared recreational doses (e.g. ~10 mg/day ligandrol in case narratives) far exceed multi-dose trial daily doses. trial
  • Liver — stacked case enzymes: Cardaci LGD+MK-677: AST +95.8%, ALT +205% on-cycle (trended toward baseline post-cycle in that subject). trial
  • Multi-SARM combination DILI pattern: Adverse-event reviews note liver injury with ostarine, RAD-140, and LGD individually and in combination; attribution to one molecule is often impossible without analytic confirmation of the product. trial
  • Product / mislabel risk (structural): JAMA 2017 — of 44 products sold as SARMs, only ~52% contained a SARM; ~39% another unapproved drug; ~25% substances not on the label; ~9% no active; only ~41% matched labeled amount. Stacks and blends magnify this. trial
  • FDA class warning: Bodybuilding SARM products linked to liver toxicity, lipid harm, and potential increased risk of heart attack and stroke in consumer warnings. trial
  • Cardarine animal carcinogenicity (adjunct risk): High-dose chronic rodent studies in development history showed multi-organ cancer signals (often cited ~3 mg/kg/day class exposures over long durations); human long-term safety is not established — major recomp-stack caution when GW is included. Community dose-conversion debates do not erase the developmental stop. animal
  • Bone note (Cardaci n=1): Transient BMC/BMD decreases on-cycle that largely recovered post-cycle — unexpected vs SARM bone-anabolic preclinical story; do not overgeneralize from one case. trial
  • Sport bans: WADA-prohibited class agents; multi-agent use multiplies positive risk; supplement contamination defenses appear in anti-doping cases. trial
  • Not risk-free framing: “Recomp without AAS” marketing ≠ proven multi-oral safety, hepatotoxicity freedom, or cardiovascular neutrality. Tissue-selectivity lore does not cancel HPTA suppression or DILI case reports. forumtrial
  • Research-only posture: Educational documentation of community and trial discourse only — not instructions for use. trial

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →